Last reviewed 2026-04-23 · How we verify

Maraviroc + Zidovudine/Lamivudine

Maraviroc + Zidovudine/Lamivudine is a CCR5 antagonist + nucleoside reverse transcriptase inhibitors (NRTIs) Small molecule drug developed by ViiV Healthcare. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve or treatment-experienced patients with CCR5-tropic virus.

This combination blocks HIV entry into CD4+ T cells via CCR5 antagonism while simultaneously inhibiting reverse transcriptase to suppress viral replication.

This combination blocks HIV entry into CD4+ T cells via CCR5 antagonism while simultaneously inhibiting reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naïve or treatment-experienced patients with CCR5-tropic virus.

At a glance

Mechanism of action

Maraviroc is a CCR5 antagonist that prevents HIV from binding to the CCR5 co-receptor on the surface of CD4+ T cells, blocking viral entry. Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase, preventing conversion of viral RNA to DNA and blocking viral replication. Together, they provide complementary mechanisms targeting both viral entry and replication.

Approved indications

• HIV-1 infection in treatment-naïve or treatment-experienced patients with CCR5-tropic virus

Common side effects

• Upper respiratory tract infection
• Cough
• Pyrexia
• Rash
• Diarrhea
• Nausea
• Headache
• Abdominal pain

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
• Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio (PHASE3)
• Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
• An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
• Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir (PHASE3)
• MARCH Vascular Endothelium Substudy
• MARCH Central Nervous System Substudy

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Maraviroc + Zidovudine/Lamivudine CI brief — competitive landscape report
• Maraviroc + Zidovudine/Lamivudine updates RSS · CI watch RSS
• ViiV Healthcare portfolio CI

Frequently asked questions about Maraviroc + Zidovudine/Lamivudine

Related

• Drug class: All CCR5 antagonist + nucleoside reverse transcriptase inhibitors (NRTIs) drugs
• Target: All drugs targeting CCR5 co-receptor; HIV reverse transcriptase
• Manufacturer: ViiV Healthcare — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection in treatment-naïve or treatment-experienced patients with CCR5-tropic virus
• Compare: Maraviroc + Zidovudine/Lamivudine vs similar drugs
• Pricing: Maraviroc + Zidovudine/Lamivudine cost, discount & access